Eli Lilly announces Verzenio survival benefit
Breast cancer is the most common cancer in women worldwide, with more than two million new cases diagnosed in 2018.
Read More
Tag: abemaciclib
NICE nod for breast cancer delay drug
Eli Lilly’s Verzenio has been recommended for use within the Cancer Drugs Fund by NICE.
Read More
NICE approval for Verzenios in metastatic breast cancer
The National Institute for Health and Care Excellence has recommended Eli Lilly’s Verzenios in combination with an aromatase inhibitor as treatment option for locally advanced or metastatic breast cancer
Read More
NICE rejects Lilly’s breast cancer drug Verzenios
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Read More
EU nod for Lilly’s new breast cancer drug
Eli Lilly’s CDK 4 and 6 inhibitor Verzenios has been approved in Europe for the treatment of certain metastatic breast cancers.
Read More
Lilly’s Verzenio bags third breast cancer nod
Eli Lilly’s Verzenio has been given another green light in the US for breast cancer, significantly expanding the drug’s treatment scope.
Read More
EU, US approvals for Faslodex combinations
AstraZeneca’s Faslodex has been cleared on both sides of the Atlantic for use in combination with a CDK4/6 inhibitor.
Read More
Lilly’s Verzenio misses key survival goal in lung cancer
Eli Lilly’s breast cancer drug Verzenio has failed to improve overall survival in a late-stage study assessing the drug’s potential in patients with KRAS-mutated, advanced non-small lung cancer (NSCLC).
Read More
Priority review for Lilly’s breast cancer drug
Eli Lilly’s experimental breast cancer drug abemaciclib has been granted a priority review by US regulators for two indications, and is now on track to be filed in Europe later this year.
Read More
Lilly reports positive data for breast cancer drug
Eli Lilly is gearing up to file data for its experimental breast cancer drug abemaciclib after it was found to slow disease progression in a late-stage trial.
Read More
Come-back for Lilly’s breast cancer drug
An experimental breast cancer combination being developed by Eli Lilly has hit its key goal of extending progression-free survival (PFS) in certain patients with advanced disease.
Read More
Lilly’s experimental breast cancer drug slips in trial
Lilly’s experimental breast cancer therapy abemaciclib has failed to hit interim efficacy targets in a late-stage combination trial, but the study will continue as planned on the recommendation of an independent data monitoring committee.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
